- Home
- ATOS vs IHD Comparison
ATOS vs IHD Comparison
Compare ATOS & IHD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATOS
- IHD
- Stock Information
- Founded
- ATOS 2009
- IHD 2011
- Country
- ATOS United States
- IHD United States
- Employees
- ATOS N/A
- IHD N/A
- Industry
- ATOS Biotechnology: Pharmaceutical Preparations
- IHD Investment Managers
- Sector
- ATOS Health Care
- IHD Finance
- Exchange
- ATOS Nasdaq
- IHD Nasdaq
- Market Cap
- ATOS 112.7M
- IHD 108.0M
- IPO Year
- ATOS 2012
- IHD N/A
- Fundamental
- Price
- ATOS $1.01
- IHD $6.26
- Analyst Decision
- ATOS Strong Buy
- IHD
- Analyst Count
- ATOS 3
- IHD 0
- Target Price
- ATOS $6.25
- IHD N/A
- AVG Volume (30 Days)
- ATOS 762.2K
- IHD 27.7K
- Earning Date
- ATOS 11-11-2025
- IHD 01-01-0001
- Dividend Yield
- ATOS N/A
- IHD 10.32%
- EPS Growth
- ATOS N/A
- IHD N/A
- EPS
- ATOS N/A
- IHD N/A
- Revenue
- ATOS N/A
- IHD N/A
- Revenue This Year
- ATOS N/A
- IHD N/A
- Revenue Next Year
- ATOS N/A
- IHD N/A
- P/E Ratio
- ATOS N/A
- IHD N/A
- Revenue Growth
- ATOS N/A
- IHD N/A
- 52 Week Low
- ATOS $0.55
- IHD $4.49
- 52 Week High
- ATOS $1.66
- IHD $5.47
- Technical
- Relative Strength Index (RSI)
- ATOS 77.26
- IHD 65.40
- Support Level
- ATOS $0.81
- IHD $6.16
- Resistance Level
- ATOS $0.90
- IHD $6.27
- Average True Range (ATR)
- ATOS 0.04
- IHD 0.06
- MACD
- ATOS 0.02
- IHD 0.00
- Stochastic Oscillator
- ATOS 83.33
- IHD 83.33
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
About IHD Voya Emerging Markets High Income Dividend Equity Fund
Voya Emerging Markets High Dividend Equity Fund is a diversified closed-end management investment company. Its primary investment objective is to provide total return through a combination of current income, capital gains, and capital appreciation. The company seeks to achieve its investment objectives by investing principally in a portfolio of equity securities, and issuers in emerging market countries. The Fund will also normally seek to secure gains and enhance the stability of returns over a market cycle by writing (selling) call options on selected exchange-traded funds (ETFs) and/or international, regional, or country indices of equity securities, and/or on equity securities.